| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | 0.067 | 0.07 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.093 | 0.07 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.062 | 0.07 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.07 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.08 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.08 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.09 | 0.08 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | 0.053 | 0.08 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.063 | 0.08 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.08 |